Project Grant R21AI187635
Award Date
11/12/24
Completion Date
10/31/26
Dollars Obligated
$182K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,730 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin - Madison. The 5-year grant, effective from December 1, 2024 to November 30, 2029, will support research to elucidate the mechanisms by which prophages (viral DNA) in the gut symbiont Limosilactobacilus reuteri modulate the production of the antimicrobial compound reuterin. The research aims to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $427,625 to the University of Wisconsin-Madison to develop an innovative approach for producing recombinant therapeutic proteins in probiotic bacteria. The goal is to create a dietary sugar-regulated system for expressing proteins like interleukin-22 in the gastrointestinal tract, without relying on antibiotic...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $560,178 Project Grant to the University of Wisconsin - Madison. The goal of this 5-year grant, which runs from Jul 25, 2025 to Jun 30, 2030, is to understand the dynamics of the interaction between Staphylococcus aureus bacteriophages, the bacteria, and the mammalian host. Specifically, the research aims to elucidate the...
This $649,053 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research by The Washington University to investigate the role of Ly49 family receptors on CD8 T cells. The central hypothesis is that immunization expands the sub-population of CD8 regulatory T cells (Tregs) that can resolve immune responses, and that Ly49 and the transcription factor Helios...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $233,250.00 to the University of Wisconsin-Madison to conduct research on the role of Brucella TIR-NAD hydrolase activity in immune suppression and pathogenesis. The research aims to determine if TIR-mediated NAD+ hydrolysis by Brucella effectors BtpA and BtpB contributes to their immunosuppressive properties and...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate a newly identified population of CD1a-restricted T cells that respond to the lipid antigen phosphatidylglycerol (PG). The total funding amount is $239,348, with the award period running from January 17, 2025 to December 31, 2026. The research aims to determine the conditions under...
This federal Project Grant award of $692,689 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to advance understanding of pegivirus persistence and immune control. The primary research objectives are to: Determine the adaptive immune functions responsible for "semi-control" of mouse-adapted pegivirus (MAPGV) infection in wild-type mice. This will involve using immune gene-knockout mice and lymphocyte...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $3,204,624.00 to the University of Pennsylvania to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The goal is to provide essential insight for developing improved therapeutics to reduce human sepsis and enhance immune responses to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $243,750 to the University of Wisconsin - Madison to investigate how the bacteria Gardnerella promotes the pathogenesis of Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhea. The research aims to determine the mechanisms by which two Gardnerella virulence factors, vaginolysin and sialidase,...
This federal Project Grant award of $183,701 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The award will support a research project at the University of Pittsburgh titled "Identification of Post-Translationally Modified Antigens Using Genetic Code Expansion". The project aims to develop a scalable platform for presenting thousands of epitopes with precisely defined...